PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma

Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.